This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Preliminary Report

SOL ROME, M.D.

AMA Arch Ophthalmol. 1957;57(2):190-199.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Recent investigations indicate that one of the major factors in the development of atherosclerosis is the state of the circulating blood lipids, or, more precisely, of the blood lipoproteins.^1,2 Heparin apparently plays a major role in the degradation or interconversion of lipoproteins from larger to smaller molecules, during their serum transport phase.^3,4 It has been postulated that endogenous heparin may be involved in a homeostatic mechanism controlling the serum transport phase of fat metabolism, similarly as insulin does in carbohydrate metabolism.^5,6 Because of its fat-clearing, or lipemia-clearing, action heparin is being used as an antiatherogenic agent; this represents a new approach to the therapy of atherosclerosis. Engelberg⁷ has suggested that heparin might be of value in the treatment of eye conditions associated with arteriosclerosis. Maumenee⁸ reviewed some of the present concepts of the pathogenesis of atherosclerosis and concluded: "One encouraging lead has emerged from the . . . [Full Text PDF of this Article]

Author Affiliations
Los Angeles

Footnotes
Received for publication June 11, 1956.

Presented before the Section of Ophthalmology of the Los Angeles County Medical Association, May 3, 1956.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?